Skip to main content

Advertisement

SpringerLink
Log in

Fistulating Anal Crohn’s Disease: Results of Combined Surgical and Infliximab Treatment

  • Published:
Diseases of the Colon & Rectum

Introduction

Infliximab is a monoclonal antibody against tumor necrosis factor-alpha, which has been shown to be effective in fistulating Crohn’s disease. The safety of infliximab in patients with potential perianal sepsis is uncertain. This study was designed to assess the safety and outcome of infliximab therapy combined with surgery for patients with fistulating anal Crohn’s disease.

Methods

All patients receiving infliximab for fistulating anal Crohn’s disease between 2000 and 2004 were studied. Patients’ demographics, clinical findings, magnetic resonance imaging, and examination under anesthesia were recorded. Perianal Crohn’s disease activity index before and 8 to 12 weeks after three infusions of infliximab (5 mg/kg) were recorded. Routine policy was to insert drainage seton sutures at the time of preinfliximab examination under anesthesia and then remove it after the second infusion. Complications of treatment and outcome at the last clinic follow-up were recorded.

Results

Twenty-two patients underwent infliximab treatment (6 males; median age, 35 (range, 16–60) years). Twenty-one patients had preinfliximab examination under anesthesia: 12 required abscess drainage; 17 had at least one drainage seton suture inserted. Fourteen patients underwent pretreatment magnetic resonance imaging to identify clinically occult collections. All but one patient were established on immunomodulator therapy before infliximab treatment. Perianal Crohn’s disease activity index improved significantly after infliximab infusion (preinfusion: median, 11, range, 8–17; postinfusion: median, 8, range, 5–16; P< 0.001). There were no serious complications of infliximab treatment. At median follow-up of 21 (range, 4–31) months, only four patients achieved sustained fistula healing. Five patients have required defunctioning or proctectomy. Four patients have required repeated infusions of infliximab.

Conclusions

Infliximab therapy in combination with examination under anesthesia/seton drainage is a safe and effective short-term treatment for fistulating anal Crohn’s disease. Long-term fistula healing rates are low.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1
Figure 2

Similar content being viewed by others

References

  1. B Singh NJ Mortensen DP Jewell BD George (2004) ArticleTitlePerianal Crohn’s disease Br J Surg 91 801–814 Occurrence Handle15227686 Occurrence Handle1:STN:280:DC%2BD2czitlyhsA%3D%3D Occurrence Handle10.1002/bjs.4613

    Article  PubMed  CAS  Google Scholar 

  2. J Alexander-Williams P Buchmann (1980) ArticleTitlePerianal Crohn’s disease World J Surg 4 203–208 Occurrence Handle7405258 Occurrence Handle1:STN:280:DyaL3c3mtFarsQ%3D%3D Occurrence Handle10.1007/BF02393577

    Article  PubMed  CAS  Google Scholar 

  3. LH Bernstein MS Frank LJ Brandt SJ Riley (1980) ArticleTitleHealing of perineal Crohn’s disease with metronidazole Gastroenterology 79 357–365 Occurrence Handle7399243 Occurrence Handle1:STN:280:DyaL3c3ksleltg%3D%3D

    PubMed  CAS  Google Scholar 

  4. JJ O’Brien TM Bayless JA Bayless (1991) ArticleTitleUse of azathioprine or 6-mercaptopurine in the treatment of Crohn’s disease Gastroenterology 101 39–46 Occurrence Handle2044925 Occurrence Handle1:STN:280:By6B2MjltlM%3D

    PubMed  CAS  Google Scholar 

  5. DH Present BI Korelitz N Wisch JL Glass DB Sachar BS Pasternack (1980) ArticleTitleTreatment of Crohn’s disease with 6-mercaptopurine. A long-term, randomized, double-blind study N Engl J Med 302 981–987 Occurrence Handle6102739 Occurrence Handle1:STN:280:DyaL3c7msFelsw%3D%3D Occurrence Handle10.1056/NEJM198005013021801

    Article  PubMed  CAS  Google Scholar 

  6. DH Present P Rutgeerts S Targan et al. (1999) ArticleTitleInfliximab for the treatment of fistulas in patients with Crohn’s disease N Engl J Med 340 1398–1405 Occurrence Handle10228190 Occurrence Handle1:CAS:528:DyaK1MXjtF2mu74%3D Occurrence Handle10.1056/NEJM199905063401804

    Article  PubMed  CAS  Google Scholar 

  7. BE Sands MA Blank RH Diamond JP Barrett SJ Deventer Particlevan (2006) ArticleTitleMaintenance infliximab does not result in increased abscess development in fistulizing Crohn’s disease: results from the ACCENT II study Aliment Pharmacol Ther 23 1127–1136 Occurrence Handle16611273 Occurrence Handle1:CAS:528:DC%2BD28Xlt1aktbw%3D Occurrence Handle10.1111/j.1365-2036.2006.02878.x

    Article  PubMed  CAS  Google Scholar 

  8. EJ Irvine (1995) ArticleTitleUsual therapy improves perianal Crohn’s disease as measured by a new disease activity index. McMaster IBD Study Group J Clin Gastroenterol 20 27–32 Occurrence Handle7884173 Occurrence Handle1:STN:280:DyaK2M7ptVansw%3D%3D Occurrence Handle10.1097/00004836-199501000-00008

    Article  PubMed  CAS  Google Scholar 

  9. U Turunen M Farkkila K Seppala (1989) ArticleTitleLong-term treatment of perianal or fistulous Crohn’s disease with ciprofloxacin [abstract] Scand J Gastroenterol 24 IssueIDSuppl 158 144

    Google Scholar 

  10. RJ Farrell SA Shah PJ Lodhavia et al. (2000) ArticleTitleClinical experience with infliximab therapy in 100 patients with Crohn’s disease Am J Gastroenterol 95 3490–3497 Occurrence Handle11151882 Occurrence Handle1:CAS:528:DC%2BD3MXmtVWmug%3D%3D Occurrence Handle10.1111/j.1572-0241.2000.03366.x

    Article  PubMed  CAS  Google Scholar 

  11. WJ Sandborn BG Feagan SB Hanauer et al. (2001) ArticleTitleAn engineered human antibody to TNF (CDP571) for active Crohn’s disease: a randomized double-blind placebo-controlled trial Gastroenterology 120 1330–1338 Occurrence Handle11313302 Occurrence Handle1:CAS:528:DC%2BD3MXjs1Srtrg%3D Occurrence Handle10.1053/gast.2001.24042

    Article  PubMed  CAS  Google Scholar 

  12. RL West CJ vanderWoude BE Hansen et al. (2004) ArticleTitleClinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn’s disease with infliximab: a double-blinded placebo-controlled study Aliment Pharmacol Ther 209 1329–1336 Occurrence Handle10.1111/j.1365-2036.2004.02247.x Occurrence Handle1:CAS:528:DC%2BD2MXoslSlsg%3D%3D

    Article  CAS  Google Scholar 

  13. J Keane S Gershon RP Wise et al. (2001) ArticleTitleTuberculosis associated with infliximab, a tumor necrosis factor-neutralizing agent N Engl J Med 345 1098–1104 Occurrence Handle11596589 Occurrence Handle1:CAS:528:DC%2BD3MXnsFShsr0%3D Occurrence Handle10.1056/NEJMoa011110

    Article  PubMed  CAS  Google Scholar 

  14. SL Brown MH Greene SK Gershon et al. (2002) ArticleTitleTumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration Arthritis Rheum 46 3151–3158 Occurrence Handle12483718 Occurrence Handle1:CAS:528:DC%2BD3sXjslGisg%3D%3D Occurrence Handle10.1002/art.10679

    Article  PubMed  CAS  Google Scholar 

  15. R Farrell M Alsahli Y Jeen K Falchuk M Peppercorn P Michetti (2003) ArticleTitleIntravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn’s disease: a randomized controlled trial Gastroenterology 124 917–924 Occurrence Handle12671888 Occurrence Handle1:CAS:528:DC%2BD3sXjsFOjurc%3D Occurrence Handle10.1053/gast.2003.50145

    Article  PubMed  CAS  Google Scholar 

  16. SB Hanauer BG Feagan GR Lichtenstein et al. (2002) ArticleTitleMaintenance infliximab for Crohn’s disease: the ACCENT I randomized trial Lancet 359 1541–1549 Occurrence Handle12047962 Occurrence Handle1:CAS:528:DC%2BD38Xkt1Gru70%3D Occurrence Handle10.1016/S0140-6736(02)08512-4

    Article  PubMed  CAS  Google Scholar 

  17. JF Colombel EV Loftus SuffixJr WJ Tremaine et al. (2004) ArticleTitleThe safety profile of infliximab in patients with Crohn’s disease: the Mayo Clinic experience in 500 patients Gastroenterology 126 19–31 Occurrence Handle14699483 Occurrence Handle1:CAS:528:DC%2BD2cXhtFGnt7c%3D Occurrence Handle10.1053/j.gastro.2003.10.047

    Article  PubMed  CAS  Google Scholar 

  18. T Ljung P Karlen D Schmidt et al. (2004) ArticleTitleInfliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County Gut 53 849–853 Occurrence Handle15138212 Occurrence Handle1:STN:280:DC%2BD2c3mtlymtA%3D%3D Occurrence Handle10.1136/gut.2003.018515

    Article  PubMed  CAS  Google Scholar 

  19. DR Topstad R Panaccione JA Heine RE Johnson AR Maclean D Buie (2003) ArticleTitleCombined seton placement, infliximab infusion and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn’s disease Dis Colon Rectum 46 577–583 Occurrence Handle12792431 Occurrence Handle10.1007/s10350-004-6611-4

    Article  PubMed  Google Scholar 

  20. C Talbot PM Sagar MJ Johnston PJ Finan D Burke (2005) ArticleTitleInfliximab in the surgical management of complex fistulating anal Crohn’s disease Colorectal Dis 7 164–168 Occurrence Handle15720356 Occurrence Handle1:STN:280:DC%2BD2M%2FptFagtA%3D%3D Occurrence Handle10.1111/j.1463-1318.2004.00749.x

    Article  PubMed  CAS  Google Scholar 

  21. G Assche ParticleVan D Vanbeckevoort D Bielen et al. (2003) ArticleTitleMagnetic resonance imaging of the effects of infliximab on perianal fistulating Crohn’s disease Am J Gastroenterol 98 332–339 Occurrence Handle12591051 Occurrence Handle10.1111/j.1572-0241.2003.07241.x

    Article  PubMed  Google Scholar 

  22. BE Sands MA Blank K Patel SJ Deventer Particlevan (2004) ArticleTitleACCENT II study. Long-term treatment of rectovaginal fistulas in Crohn’s disease: response to infliximab in the ACCENT II Study Clin Gastroenterol Hepatol 2 912–20 Occurrence Handle15476155 Occurrence Handle1:CAS:528:DC%2BD2cXps1ahtb0%3D Occurrence Handle10.1016/S1542-3565(04)00414-8

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Colorectal Surgery, John Radcliffe Hospital, Oxford, OX3 9DU, United Kingdom

    Syed A. Hyder F.R.C.S., Neil J. McC. Mortensen F.R.C.S. & Bruce D. George F.R.C.S.

  2. Department of Gastroenterology, John Radcliffe Hospital, Oxford, United Kingdom

    Simon P. L. Travis F.R.C.P. & Derek P. Jewell F.R.C.P.

Authors
  1. Syed A. Hyder F.R.C.S.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Simon P. L. Travis F.R.C.P.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Derek P. Jewell F.R.C.P.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Neil J. McC. Mortensen F.R.C.S.
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bruce D. George F.R.C.S.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bruce D. George F.R.C.S..

About this article

Cite this article

Hyder, S.A., Travis, S.P.L., Jewell, D.P. et al. Fistulating Anal Crohn’s Disease: Results of Combined Surgical and Infliximab Treatment. Dis Colon Rectum 49, 1837–1841 (2006). https://doi.org/10.1007/s10350-006-0656-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10350-006-0656-5

Key words

Search

Navigation